56. In vitro and preclinical studies of targeted alpha therapy for human breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2

Citation

• Allen, B. J., Tian, Z., Andronicos, N. M., Rizvi, S., & Ranson, M. (2001). 56. In vitro and preclinical studies of targeted alpha therapy for human breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. Nuclear Medicine Communications, 22(8), 939-940. doi:10.1097/00006231-200108000-00066

Digital Object Identifier (doi)

• 10.1097/00006231-200108000-00066

Web Of Science Accession Number

Start Page

• 939

End Page

• 940

Volume

• 22

Issue

• 8

Abstract

UOW Authors

•   Ranson, Marie

Publication Date

• 2001

Publisher

• Ovid Technologies (Wolters Kluwer Health) 

Published In

• Nuclear Medicine Communications  Journal

Citation

• Allen, B. J., Tian, Z., Andronicos, N. M., Rizvi, S., & Ranson, M. (2001). 56. In vitro and preclinical studies of targeted alpha therapy for human breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. Nuclear Medicine Communications, 22(8), 939-940. doi:10.1097/00006231-200108000-00066

Digital Object Identifier (doi)

• 10.1097/00006231-200108000-00066

Web Of Science Accession Number

Start Page

• 939

End Page

• 940

Volume

• 22

Issue

• 8